Elicio Therapeutics to Present New Preliminary Data From the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients With MKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the

GlobeNewswireApr 25 08:30 ET

Elicio Therapeutics Celebrates 13 Years Developing Innovative Cancer Immunotherapies

ProdigyPressApr 24 12:20 ET

Robert Connelly Elicio Therapeutics, Inc.'s (NASDAQ:ELTX) CEO Is the Most Bullish Insider, and Their Stock Value Gained 11%last Week

Yahoo FinanceApr 13 09:19 ET

12 Health Care Stocks Moving In Friday's After-Market Session

GainersLongeveron (NASDAQ:LGVN) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at $8.2 million. Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by

BenzingaApr 5 16:31 ET

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data From the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

Elicio Therapeutics today announced that it will be sharing pipeline updates for all investigational candidates at the upcoming American Association for Cancer Research ("AACR") Annual Meeting, taking place in San Diego, California from April 5-10, 2024.

GlobeNewswireApr 5 16:30 ET

Express News | Oppenheimer Reiterates Perform on Elicio Therapeuticsto Perform

Moomoo 24/7Apr 1 09:21 ET